// App-Quantinova.ai

Sa1918 : Better off NaiVE: Predictors of Adalimumab Dose Escalation in Patients With Crohn's Disease

Researchers

Presenter

  • Karli Moncrief

Principal Investigators

  • A. Steinhart

  • K. Croitoru

  • A. Newman

  • G. Nguyen

  • W. Xu

  • M. Silverberg

Medical Centers

  • Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON, Canada

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Division of General Surgery, University of Toronto, Toronto, ON, Canada

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Anal fistula

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • Infliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved